Northwest Quadrant Wealth Management LLC Decreases Stock Holdings in Johnson & Johnson $JNJ

Northwest Quadrant Wealth Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 6.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,468 shares of the company’s stock after selling 296 shares during the period. Johnson & Johnson accounts for approximately 0.2% of Northwest Quadrant Wealth Management LLC’s portfolio, making the stock its 26th largest holding. Northwest Quadrant Wealth Management LLC’s holdings in Johnson & Johnson were worth $683,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Raymond James Financial upped their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. HSBC upped their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Finally, Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $200.06.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $193.78 on Tuesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a 50 day moving average price of $180.89 and a 200 day moving average price of $165.18. The firm has a market capitalization of $466.68 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion during the quarter. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.